HC Wainwright & Co. Downgrades Entrada Therapeutics to Neutral

Benzinga Newsdesk www.benzinga.com Negative 90.2%

Neg 90.2% Neu 0% Pos 0%

HC Wainwright & Co. analyst Raghuram Selvaraju downgrades Entrada Therapeutics (NASDAQ:TRDA) from Buy to Neutral.

Comments

No comments yet. Be the first!